The prevalence of diabetes mellitus in China is close to 10%, and its serious complication, diabetic foot, is becoming more and more common, resulting in the first of the non-traumatic amputation factors, with one diabetic patient having an amputation every 30 seconds and high early and mid-late postoperative mortality. Diabetic peripheral neuropathy is the most important cause of diabetic foot, and research in this area is of great value. Traditionally, the disease is thought to be associated with a variety of factors, mainly metabolic disorders caused by hyperglycemia, microangiopathy and nerve growth factor deficiency. The treatment is mostly based on the control of blood glucose with neurotrophic drugs such as B vitamins like adenosine cobalamin, nerve growth factor, gangliosides, etc., microcirculatory drugs such as prostaglandins, free radical scavenging drugs such as lipoic acid and symptomatic analgesic treatment, but none of them have significant effect. Dellon of Hopkins University proposed a new hypothesis: peripheral nerves in diabetic patients swell due to accumulation of glycosylation products, forming a jam in the narrow area of nerve travel, and chronic jamming leads to microvascular ischemia in the outer membrane of the nerve and demyelination changes, resulting in sensory abnormalities and motor deficits. The Dellon lower extremity triple incision procedure was developed to decompress the common peroneal, deep peroneal, and posterior tibial nerves in the lower extremity. The shortcoming of the standard Dellon procedure is that it is too invasive, and minimally invasive surgery at the end of the limb is particularly important for diabetic patients. Based on the author’s completion of several standard Dellon surgeries, he has completed some cases using minimally invasive surgery with good results and reduced surgical trauma.